The estimated deterministic ICER for bDMARD strategies compared with a cDMARD strategy. All numbers rounded to the nearest £100 (US$122). Data are median (mean).
| Base Case Analyses | Supplementary Analyses | |||
| Base Case | Assuming HAQ Progression in Trajectories 3 and 4 until Year 40 | Base Case | Assuming HAQ Progression in Trajectories 3 and 4 | |
| Severe RA | £41,600 (£40,800) | £40,800 (£40,100) | £25,300 (£24,800) | £23,900 (£23,500) |
| All Patients | Patients with Greatest HAQ Progression | |||
| Base Case | Assuming HAQ Progression in Trajectories 3 and 4 until Year 40 | Base Case | Assuming HAQ Progression in Trajectories 3 and 4 | |
| Moderate to severe RA | £51,100 (£49,800) | £49,100 (£48,900) | £28,500 (£28,100) | £25,700 (£25,400) |
Supplementary analyses include only patients with the most severe prognoses. ICER: incremental cost-effectiveness ratio; bDMARD: biological disease-modifying antirheumatic drug; cDMARD: conventional DMARD; RA: rheumatoid arthritis; HAQ: Health Assessment Questionnaire.